Adalimumab biosimilar (Kashiv BioSciences)

阿达木单抗生物类似药 (Kashiv BioSciences)

Report date: 2025/05/06 15:48:46

Base Information

Drug NameAdalimumab biosimilar (Kashiv BioSciences)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAdello Biologics Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKashiv BioSciences LLC
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A